Controversies in the adjuvant therapy of high-grade gliomas

Oncologist

Volumn 16, Issue 3, 2011, Pages 351-358

  Holdhoff, Matthias ^a   Grossman, Stuart A ^a  

^a JOHNS HOPKINS UNIVERSITY   (United States)

Author keywords

Adjuvant therapy; Anaplastic astrocytoma; Anaplastic oligoastrocytoma; Anaplastic oligodendroglioma; Chemotherapy; Glioblastoma multiforme; Low grade glioma; Temozolomide

Indexed keywords

BEVACIZUMAB; CARBOXYMETHYLCELLULOSE POLYCYTIDYLIC POLYINOSINIC ACID POLYLYSINE; CARMUSTINE; CILENGITIDE; ERLOTINIB; HYDROXYCHLOROQUINE; LOMUSTINE; PLACEBO; PROCARBAZINE; TALAMPANEL; TEMOZOLOMIDE; VINCRISTINE;

ARTICLE; BONE MARROW SUPPRESSION; BRAIN EDEMA; BRAIN SURGERY; CANCER ADJUVANT THERAPY; CANCER RADIOTHERAPY; CANCER SURVIVAL; CHEMORADIOTHERAPY; DOSAGE SCHEDULE COMPARISON; DRUG BRAIN LEVEL; DRUG DOSE REGIMEN; DRUG IMPLANTATION; DRUG MEGADOSE; DRUG SAFETY; DRUG WITHDRAWAL; GLIOBLASTOMA; GLIOMA; HUMAN; INFECTION; INTRACRANIAL HYPERTENSION; LIQUORRHEA; LOW DRUG DOSE; LYMPHOCYTOPENIA; MULTIPLE CYCLE TREATMENT; PRIORITY JOURNAL; THROMBOCYTOPENIA; TREATMENT DURATION; UNSPECIFIED SIDE EFFECT;

ANGIOGENESIS INHIBITORS; ANTIBODIES, MONOCLONAL; ANTINEOPLASTIC AGENTS, ALKYLATING; CARMUSTINE; CHEMOTHERAPY, ADJUVANT; FEMALE; GLIOBLASTOMA; HUMANS; MALE; TREATMENT OUTCOME;

EID: 79953005803     PISSN: 10837159     EISSN: 1549490X     Source Type: Journal    
DOI: 10.1634/theoncologist.2010-0335     Document Type: Article

References (32)

1. Stewart LA. Chemotherapy in adult high-grade glioma: A systematic review and meta-analysis of individual patient data from 12 randomised trials. Lancet 2002;359:1011-1018.
2. Stupp R, Mason WP, van den Bent MJ et al. Radiotherapy plus concomitant and adjuvant temozolomide for glioblastoma. NEngl J Med 2005;352:987-996.
3. Stupp R, Hegi ME, Mason WP et al. Effects of radiotherapy with concomitant and adjuvant temozolomide versus radiotherapy alone on survival in glioblastoma in a randomised phase III study: 5-year analysis of the EORTC-NCIC trial. Lancet Oncol 2009;10:459-466.
4. Gerber DE, Grossman SA, Zeltzman M et al. The impact of thrombocytopenia from temozolomide and radiation in newly diagnosed adults with high-grade gliomas. Neuro Oncol 2007;9:47-52.
5. Grossman SA, Ye X, Lesser GJ et al. Iatrogenic immunosuppression in patients with high-grade gliomas treated with radiation and temozolomide: A NABTT CNS Consortium study. J Clin Oncol 2010;28(15 suppl):2013.
6. Brandes AA, Franceschi E, Tosoni A et al. MGMT promoter methylation status can predict the incidence and outcome of pseudoprogression after concomitant radiochemotherapy in newly diagnosed glioblastoma patients. J Clin Oncol 2008;26:2192-2197.
7. Portnow J, Badie B, Chen M et al. The neuropharmacokinetics of temozolomide in patients with resectable brain tumors: Potential implications for the current approach to chemoradiation. Clin Cancer Res 2009;15:7092-7098.
8. Tolcher AW, Gerson SL, Denis L et al. Marked inactivation of O6-alkylguanine-DNA alkyltransferase activity with protracted temozolomide schedules. Br J Cancer 2003;88:1004 -1011.
9. Brandes AA, Tosoni A, Cavallo G et al. Temozolomide 3 weeks on and 1 week off as first-line therapy for recurrent glioblastoma: Phase II study from Gruppo Italiano Cooperativo di Neuro-Oncologia (GICNO). Br J Cancer 2006;95:1155-1160.
10. Neyns B, Chaskis C, Joosens E et al. A multicenter cohort study of dosedense temozolomide (21 of 28 days) for the treatment of recurrent anaplastic astrocytoma or oligoastrocytoma. Cancer Invest 2008;26:269-277.
11. Wick A, Felsberg J, Steinbach JP et al. Efficacy and tolerability of temozolomide in an alternating weekly regimen in patients with recurrent glioma. J Clin Oncol 2007;25:3357-3361.
12. Clarke JL, Iwamoto FM, Sul J et al. Randomized phase II trial of chemoradiotherapy followed by either dose-dense or metronomic temozolomide for newly diagnosed glioblastoma. J Clin Oncol 2009;27:3861-3867.
13. Brada M, Stenning S, Gabe R et al. Temozolomide versus procarbazine, lomustine, and vincristine in recurrent high-grade glioma. J Clin Oncol 2010;28:4601-4608.
14. Lawson HC, Sampath P, Bohan E et al. Interstitial chemotherapy for malignant gliomas: The Johns Hopkins experience. J Neurooncol 2007;83:61-70.
15. Westphal M, Hilt DC, Bortey E et al. A phase 3 trial of local chemotherapy with biodegradable carmustine (BCNU) wafers (Gliadel wafers) in patients with primary malignant glioma. Neuro Oncol 2003;5:79-88.
16. Weber EL, Goebel EA. Cerebral edema associated with Gliadel wafers: Two case studies. Neuro Oncol 2005;7:84-89.
17. McGirt MJ, Than KD, Weingart JD et al. Gliadel (BCNU) wafer plus concomitant temozolomide therapy after primary resection of glioblastoma multiforme. J Neurosurg 2009;110:583-588.
18. Friedman HS, Prados MD, Wen PY et al. Bevacizumab alone and in combination with irinotecan in recurrent glioblastoma. J Clin Oncol 2009;27: 4733-4740.
19. Verhoeff JJ, van Tellingen O, Claes A et al. Concerns about anti-angiogenic treatment in patients with glioblastoma multiforme. BMC Cancer 2009;9: 444.
20. Lucio-Eterovic AK, Piao Y, de Groot JF. Mediators of glioblastoma resistance and invasion during antivascular endothelial growth factor therapy. Clin Cancer Res 2009;15:4589-4599.
21. Keime-Guibert F, Chinot O, Taillandier L et al. Radiotherapy for glioblastoma in the elderly. N Engl J Med 2007;356:1527-1535.
22. Malmstrom A, Gronberg BH, Stupp R et al. Glioblastoma (GBM) in elderly patients:Arandomized phase III trial comparing survival in patients treated with 6-week radiotherapy (RT) versus hypofractionated RT over 2 weeks versus temozolomide single-agent chemotherapy (TMZ). J Clin Oncol 2010;28(18 suppl):2002.
23. Wick W, Engel C, Combs SE et al. NOA-08 randomized phase III trial of 1-week-on/1-week-off temozolomide versus involved-field radiotherapy in elderly (older than age 65) patients with newly diagnosed anaplastic astrocytoma or glioblastoma (Methusalem). J Clin Oncol 2010;28(18 suppl): 2001.
24. Gerstner ER, Yip S, Wang DL et al. Mgmt methylation is a prognostic biomarker in elderly patients with newly diagnosed glioblastoma. Neurology 2009;73:1509 -1510.
25. Brandes AA, Franceschi E, Tosoniaet al. Temozolomide concomitant and adjuvant to radiotherapy in elderly patients with glioblastoma: Correlation with MGMT promoter methylation status. Cancer 2009;115:3512-3518.
26. van den Bent MJ, Carpentier AF, Brandes AA et al. Adjuvant procarbazine, lomustine, and vincristine improves progression-free survival but not overall survival in newly diagnosed anaplastic oligodendrogliomas and oligoastrocytomas: A randomized European Organisation for Research and Treatment of Cancer phase III trial. J Clin Oncol 2006;24:2715-2722.
27. Intergroup Radiation Therapy Oncology Group Trial 9402, Cairncross G, Berkey B et al. Phase III trial of chemotherapy plus radiotherapy compared with radiotherapy alone for pure and mixed anaplastic oligodendroglioma: Intergroup Radiation Therapy Oncology Group Trial 9402. J Clin Oncol 2006;24:2707-2714.
28. Wick W, Hartmann C, Engel C et al. NOA-04 randomized phase III trial of sequential radiochemotherapy of anaplastic glioma with procarbazine, lomustine, and vincristine or temozolomide. J Clin Oncol 2009;27:5874-5880.
29. Grossman SA, Ye X, Chamberlain M et al. Talampanel with standard radiation and temozolomide in patients with newly diagnosed glioblastoma: A multicenter phase II trial. J Clin Oncol 2009;27:4155-4161.
30. Nabors LB, Mikkelsen T, Batchelor T et al. NABTT 0306: A randomized phase II trial ofEMD121974 in conjunction with concomitant and adjuvant temozolomide with radiation therapy in patients with newly diagnosed glioblastoma multiforme (GBM). J Clin Oncol 2009;27(15 suppl):2001.
31. Rosenfeld MR, Chamberlain MC, Grossman SA et al. A multi-institution phase II study of poly-ICLC and radiotherapy with concurrent and adjuvant temozolomide in adults with newly diagnosed glioblastoma. Neuro Oncol 2010;12:1071-1077.
32. Grossman SA, Ye X, Piantadosi S et al. Survival of patients with newly diagnosed glioblastoma treated with radiation and temozolomide in research studies in the United States. Clin Cancer Res 2010;16:2443-2449.